25/307 (8)

\* 10/111 (10.0) # 39/115 (33.9)

**Lymphedema by patients (%)** 

**<sup>N</sup>Inclusion Criteria** 

**Published studies** 

MILAN

(Veronesi et al., 1997, 2003) (negative SLN in 341patients (167SLN +174ALND) (1998-1999)

Sentinella/ GIVOM

2008) (1999-2003)

al., 2002) (1999-2004)

2010) (1999-2004)

NSABP B-32 Morbidty results (Ashikaga et al.,

NSABP B-32 Outcome study (Mansel et al., 2006)

(2001-2004)

L=lumpectomy

RT=radiotherapy

MRM=modified radical mastectomy

\*SLND=Sentinel Lymph Node

2 Odds ratio (SLN/ALN)

Wernicke et al. (Wernicke et al., 2010, 2011)

(Land et al., 2010) (1999-2004)

ALMANAC-UK (Mclaughlin et al.,

ACOSZOG Z0011 Trial (Aareleid et

**Median follow up (years)** 

3 516

1 1031

3 5611

3 749
